EYPT Stock EyePoint Pharmaceuticals (EYPT, $10.28) Aroon Indicator entered a Downtrend on August 11, 2025.

GET DAILY SIGNALS

Get AI intraday signals

EYPT - EyePoint Pharmaceuticals

Aroon signal

View

Odds of DOWN Trend

Price: $10.28

Daily change: +$0.21 (+2.04%)

Daily volume: 576.5K

Capitalization: $708.2M

Industry: Biotechnology

EYPT sees MACD Histogram crosses below signal line

EYPT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 14, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for EYPT moved out of overbought territory on July 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where EYPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EYPT entered a downward trend on August 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 11, 2025. You may want to consider a long position or call options on EYPT as a result. In of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for EYPT moved above the 200-day moving average on July 10, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EYPT advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EYPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.879) is normal, around the industry mean (18.461). P/E Ratio (0.000) is within average values for comparable stocks, (53.401). EYPT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.822). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (12.804) is also within normal values, averaging (286.886).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.